Insurance Benefits

When it comes to long-term therapies like Cerezyme®, understanding your insurance coverage is very important but it can be confusing at times. With 25 years of experience in navigating the reimbursement process for enzyme replacement therapies, Sanofi Genzyme Case Managers are knowledgeable and will work with you every step of the way.

Your Sanofi Genzyme Case Manager can help you and your physician better understand your insurance benefits so you can get access to the treatment you need.

If you currently have health insurance: Your Sanofi Genzyme Case Manager can help review your coverage options for treatment with Cerezyme and explain how your coverage will work.

If you are currently uninsured or have limited health insurance coverage: Your Sanofi Genzyme Case Manager can help you review your coverage options and if necessary, refer you to programs that may provide financial assistance for eligible applicants, including applicable state and federal programs. They can also help provide Cerezyme to eligible individuals through the Sanofi Genzyme Charitable Access Program.

If a claim has been denied by your insurance company: Call your Sanofi Genzyme Case Manager for assistance immediately. It is helpful to have a copy of the denied claim on hand when calling. Your Sanofi Genzyme Case Manager can help by working with you, your healthcare providers and insurance company to begin an appeal process, if necessary.

For help with insurance questions, please call: 1-800-745-4447, Option 3

Monday through Friday, 8:00 AM to 6:00 PM EST

A consent form is required for a Sanofi Genzyme Case Manager to work with you, your health care providers and insurance company. This service is offered at no cost to you and is completely voluntary. Any information you provide will be maintained as confidential by Sanofi Genzyme.   

Indication & Usage

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

  1. anemia (low red blood cell count)
  2. thrombocytopenia (low blood platelet count)
  3. bone disease
  4. hepatomegaly or splenomegaly (enlarged liver or spleen)

Important Safety Information

Approximately 15% of patients have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies. Serious allergic reactions (anaphylaxis) have been reported in less than 1% of patients. Symptoms suggestive of allergic reaction happened in approximately 7% of patients, and include itching, flushing, hives, swelling, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure. If you have had an allergic reaction to Cerezyme, you and your doctor should use caution if you continue to receive treatment with Cerezyme.

High blood pressure in the arteries of the lungs (pulmonary hypertension) and pneumonia have been observed in less than 1% of patients during treatment with Cerezyme. These are also known complications of Gaucher disease regardless of treatment. If you experience symptoms such as shortness of breath or chest pain, with or without fever, contact your doctor.

Approximately 14% of patients have experienced side effects related to treatment with Cerezyme. Some of these reactions occur at the site of injection such as discomfort, itching, burning, swelling or uninfected abscess. Other side effects, each of which was reported by less than 2% of patients, include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Temporary swelling in the legs has also been observed with drugs like Cerezyme.

Please see Full Prescribing Information (PDF).

You may report side effects to the FDA at 1-800-FDA-1088.

Reference 1. Data on file. Genzyme Corporation; Cambridge, MA.